Because published reports indicate that the antibiotic colistin (COL) has antifungal properties, this study investigated the antifungal in vitro activity of COL as single agent and in combination with the antifungal compounds voriconazole (VRC), caspofungin (CAS) and amphotericin B (AMB) against Scedosporium ⁄ Pseudallescheria spp., Exophiala dermatitidis and Geosmithia argillacea. In total, susceptibility was determined for 77 Scedosporium ⁄ Pseudallescheria spp., 82 E. dermatitidis and 17 G. argillacea isolates. The minimal inhibitory concentrations (MICs) of COL and the antifungals as single compound and in combination were determined with MIC test strips. Drug interactions were detected by crossing the MIC test strips at a 90º angle. The fractional inhibitory concentration index was used to categorise the drugsÕ interaction. The MIC 50 value of COL was 12 lg ml )1 for S. prolificans, 16 lg ml )1 for P. apiosperma, 16 lg ml )1 for P.
Introduction
Bacterial colonisation or infection of the respiratory tract is one of the main reasons for increased morbidity and mortality rates among cystic fibrosis (CF) patients. 1 However, the respiratory tract secretions of CF patients often contain filamentous fungi, such as Aspergillus spp.
2 Scedosporium ⁄ Pseudallescheria spp. and Exophiala dermatitidis are reported to be the most common nonAspergillus species moulds, whereas Geosmithia argillacea was recently described as an emerging pathogen in this patient population. [3] [4] [5] The prevalence of filamentous fungi in the CF community shows great interstudy and geographical variations. 3, 6 This is most likely due to differences in the procedures used for mycological examination of sputum samples (conventional vs. selective agar), the methods used for species identification (phenotypic vs. molecular) and environmental differences. In the context of CF, the exact clinical relevance of these fungal infections is still a matter of debate. However, invasive and fatal infections with Scedosporium ⁄ Pseudallescheria spp., E. dermatitidis and G. argillacea, especially in immunocompromised patients, have been repeatedly reported. [7] [8] [9] [10] [11] [12] [13] [14] Colistin (COL; polymyxin E) belongs to the antibiotic substance class of polymyxins, produced by Bacillus polymyxa. The mode of action of this antibiotic is the disruption of the outer membrane of gram-negative bacteria, which results in an increased cell permeability with subsequent leakage of cell content, cell lysis and cell death. 15 Nebulised COL is a frequently used agent for inhalation therapy in CF patients chronically colonised with Pseudomonas aeruginosa or other multidrug-resistant gram-negative rods. 16 Other authors reported that the antibiotic COL shows reasonable antifungal activity against Candida spp., Cryptococcus neoformans and Mucorales spp. 17, 18 The aim of this study was to analyse the in vitro activity of COL as single agent and in combination with voriconazole (VRC), caspofungin (CAS) and amphotericin B (AMB) against Pseudallescheria ⁄ Scedosporium spp., E. dermatitidis and G. argillacea.
Materials and methods

Isolates
In total, we tested 77 Scedosporium ⁄ Pseudallescheria spp. isolates, 82 E. dermatitidis isolates and 17 G. argillacea isolates, including 69 (39%) reference strains. The clinical isolates were obtained from the following institutions: Institute of Medical Microbiology, University Hospital Essen, Germany; Consultant Laboratory for Cystic Fibrosis-Bacteriology (Northern Germany), Institute of Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Germany; Institute for Medical Microbiology, Immunology and Hygiene, University Hospital of Cologne, Cologne, Germany; and the Collection of the ECMM-ISHAM Working Group on Pseudallescheria ⁄ Scedosporium infections.
We tested a total of 19 S. prolificans (52% isolated from CF patients, nine reference strains of international collections), 30 P. apiosperma (67% from CF, 16 reference strains) and 28 P. boydii isolates (71% from CF, 14 reference strains). Of the 82 tested E. dermatitidis isolates, 80% (n = 66) were obtained from CF patients and 34% (n = 28) were reference strains from the Centraalbureau voor Schimmelcultures (CBS), including those from CF patients. Of the tested G. argillacea strains, two isolates were CBS reference strains and 13 (76%) were obtained from CF patients. In total, 131 of the 176 (74.4%) tested fungal species were obtained from the respiratory tract of CF patients.
Molecular species identification
All clinical isolates were identified by phenotypic characteristics to the genus level. Subsequent species identification was performed using molecular methods. All isolates from Essen, Cologne and Hannover were identified by sequencing the internally transcribed spacer (ITS1-5.8S-ITS2) region of the rDNA, as described previously. 19 Isolates from the Collection of the ECMM-ISHAM Working Group on Pseudallescheria ⁄ Scedosporium Infections were identified to the species level by amplified fragment length polymorphisms, as reported. 20 Species identification of reference strains were provided by the international collections.
Susceptibility testing
Susceptibility testing for all isolates was performed according to the guidelines of the Clinical Laboratory Standards Institute (CLSI) document M38-A2. 21 However, in accordance with Pfaller et al. [22] , the CLSI test method was modified from a broth dilution method to a minimal inhibitory concentration (MIC) test strip method. The following drugs were tested as single compounds: COL, VRC, CAS and AMB. In addition, COL was tested in combination with VRC, CAS and AMB (MIC test strips; Liofilchem s.r.l., Roseto degli, Italy).
Before susceptibility testing, isolates were grown on malt extract agar (Oxoid, Hampshire, UK) at 30°C for 7 days. They were then sub-cultured on potato dextrose agar (Oxoid) and incubated at 35°C for 7 days so that adequate sporulation could be ensured.
Spore suspensions were prepared in sterile 0.9% NaCl solution, adjusted to a density of 0.5 McFarland standard and inoculated onto RPMI MOPS 2% Glucose Agar (Reactivos Para Diagnostico S.L., Barcelona, Spain). For single testing, the MIC test strip was placed in the middle of the plate. The plates were incubated at 30°C and read after 72-96 h as recommended by the manufacturer. The MIC reading in single testing was interpreted as the zone diameter of inhibition that intersected with the strip. 22 
Combination testing
In accordance with the method described by Kiraz et al. [23] , the MIC test strips were placed at a 90°angle to each other. The MIC strip was placed so that the crossing of the two strips was at the MIC 50 found in single testing for each substance. For combination testing, the COL strip was always placed first on the RPMI agar and the antifungal agent strip was placed above. The plates were incubated at 30°C and were read after 72-96 h. For combination testing, the MIC was read as each drug concentration at which the inhibition zone between the test strips met.
We determined synergistic, indifferent or antagonistic effects by using the following formula to calculate the fractional inhibitory concentration index ( 
Results
Scedosporium ⁄ Pseudallescheria spp.
The range, geometric mean, MIC 50 and MIC 90 of COL and the antifungal compounds against Scedosporium ⁄ Pseudallescheria spp. isolates (n = 77) are shown in Table 1 . The MIC 50 for COL was 12 lg ml )1 for S.
prolificans, 16 lg ml )1 for P. apiosperma and 16 lg ml
for P. boydii (Table 1) . S. prolificans exhibited high MICs (>32 lg ml
) against all tested antifungals in single testing. The MIC values for VRC and AMB against P. boydii and P. apiosperma were lower than those for S. prolificans. CAS exhibited no activity against any tested isolate (>32 lg ml )1 ).
The MICs and the FICIs determined by susceptibility testing for COL in combination with VRC, CAS and AMB are shown in Tables 2 and 3 . The MIC 50 of the combination of VRC and COL were decreased for both substances and the combination exerted no antagonistic effects against the tested species with the exception of some P. boydii isolates (11%). The interaction of CAS and COL against P. boydii and P. apiosperma increased the MIC 50 of COL up to 256 lg ml )1 , resulting in a high rate of antagonism (>50%). The MIC 50 of AMB in single testing against all tested isolates was >32 lg ml )1
. When AMB was tested in combination with COL against S. prolificans, no antagonistic effects were detected. This combination resulted in fewer than 25% antagonistic effects against P. apiosperma, but in 54% antagonism against P. boydii isolates. For these last two species, the MIC 50 of COL in combination with AMB was as much as six times higher than the MIC 50 of COL alone. 
Exophiala dermatitidis
The range, geometric mean, MIC 50 and MIC 90 of COL against all tested E. dermatitidis isolates (n = 82) are shown in Table 1 . The combination of COL and VRC was synergistic against 20% of isolates, and no antagonism was observed ( ). Interestingly, the MIC 50 of CAS decreased from >32 lg ml )1 to 7 lg ml )1 when COL
and CAS were applied in combination; this decrease resulted in a rate of synergy against 7.3% of the strains. AMB alone exhibited low MICs against all isolates (MIC 50 , 0.25 lg ml )1 ). When AMB was tested in combination with COL, the MIC 50 of both drugs decreased and showed indifference to 95% of the isolates.
Geosmithia argillacea
The range, geometric mean, MIC 50 and MIC 90 of COL against all tested G. argillacea isolates (n = 17) are shown in Table 1 . VRC alone and AMB alone did not exert any antifungal activity (MIC 50 , 32 lg ml )1 for both substances). The combination of COL and CAS was antagonistic against 88% of G. argillacea isolates. When COL was combined with either AMB or VRC, only indifferent effects were observed, but the MIC 50 of AMB and VRC decreased from >32 to 2 lg ml )1 and to 0.5 lg ml )1 respectively.
Discussion
In this study, we could demonstrate that the antibiotic COL has besides its bactericidal activity also antifungal activity against Scedosporium ⁄ Pseudallescheria spp., E. dermatitidis and G. argillaceae. In addition, we showed that combining COL with antifungal substances could reduce the MIC values of antifungal agentsÕ species specific. Based on the in vitro data, COL might be considered as a novel agent for the antifungal therapy in combination with an antifungal compound. Infections in CF patients with the emerging fungal pathogen S. prolificans can be life-threatening due to the therapy-refractory nature of this fungus. 12 As shown in this study and by others, S. prolificans is resistant to nearly all antifungals tested as single agent. 20, [25] [26] [27] One novelty of our study is the finding that COL exerts in vitro antifungal activity against S. prolificans (MIC 90 = 12 lg ml )1 ). To the best of our knowledge, no other single agent that is approved for clinical use has to date demonstrated such low MIC value and this fact suggests that the efficacy of COL may be superior to that of any other antifungal agent against S. prolificans. The combination of either ravuconazole and CAS or terbinafine and miconazole or VRC and micafungin has been reported to be synergistic against S. prolificans. 25, 28, 29 We could also show that the combination of COL and VRC at low concentrations inhibits the growth of S. prolificans. In addition, no antagonism against S. prolificans was observed when COL was combined with VRC, CAS or AMB.
In general, clinical practice, COL is administered via inhalation as a common prophylaxis and also as treatment for chronic P. aeruginosa colonisation in CF patients. In a pharmacokinetic study, Ratjen and colleagues demonstrated that inhalation of 2 million units of COL produces a sputum peak above 30 lg ml )1 after 90 min and reaches sputum levels higher than 12 lg ml )1 for 8 h after administration. 30 Thus, inhalation twice daily is recommended for maintaining sufficient sputum concentrations of COL. 30 However, one must consider whether a peak COL concentration >30 lg ml )1 can actually exhibit fungicidal effects in the lungs of CF patients. Nonetheless, our in vitro data suggest that COL may exert antifungal therapeutic effects alone or in combination with antifungal agents. COL was found to have in vitro activity against nonAspergillus moulds from the genus Mucorales and in combination with AMB also exerts synergistic activity against Rhizopus oryzae.
18 More importantly, the results of in vivo experiments have demonstrated that the prophylactic intranasal administration of colistimethate to intranasally infected immunosuppressed mice harbouring R. oryzae spores resulted in a higher survival rate and a lower fungal burden than in untreated control mice. 18 The authors suggested that preclinical and clinical studies evaluating the use of COL for the treatment of mucormycosis should be conducted promptly.
The activity of polymyxin B in combination with fluconazole against C. neoformans, C. albicans and nonalbicans Candida species has been previously assessed. 17 This study showed that polymyxin B plus fluconazole was potent at low concentrations against C. neoformans isolates. The authors postulated that this drug combination could potentially be an effective treatment option for cryptococcal meningitis.
Because A. fumigatus is the mould most frequently isolated in samples from CF patients, we also tested several isolates of this species. In agreement with the findings of a previous study, 18 we found that COL as single agent exerted no antifungal activity (MIC > 2 lg ml )1 ) against A. fumigatus isolates (n = 10) from CF patients (data not shown).
As shown by Gilgado et al. [31] and by Lackner et al. [20] , P. boydii exhibits high MIC values for AMB, but VRC shows good antifungal activity in vitro. In our study, the highest MICs for COL were also recorded among P. boydii isolates (MIC 90 = 36.8 lg ml )1 ). Furthermore, the combination of COL with either CAS or AMB exerted antagonistic effects of more than 50% against P. boydii. These findings underline the importance of correct identification and determination of the clade origin of the isolate, because the Scedosporium ⁄ Pseudallescheria spp. are known to have heterogenous antifungal susceptibilities. 20, 31 As pointed out recently, susceptibility testing for targeted therapy against Scedosporium ⁄ Pseudallescheria species is recommended because of a wide MIC distribution for most substances. 20 Our findings confirm these observations: the activity of COL alone and in combination greatly differs among the various species of this genus.
Single testing of COL against E. dermatitidis yielded results that were not superior to those of VRC or AMB, for which low MIC values were recorded. However, the Table 3 Combination testing of colistin (COL) with voriconazole (VRC), caspofungin (CAS) and amphotericin B (AMB) against Scedosporium prolificans, Pseudallescheria apiospermum, P.
boydii, Exophiala dermatitidis and Geosmithia argillacea by MIC test strips.
S. prolificans (n = 19) combination of COL with the less-effective drug CAS resulted in a fourfold MIC 50 of CAS. Moreover, the combination of COL and VRC exhibited synergistic effects in up to 20% of isolates. Consequently, COL seems to have no major disadvantages in combination with antifungal agents against E. dermatitidis.
Like in previous studies, we also found high MICs for VRC and low MICs for CAS in G. argillacea isolates from CF patients. 4, 5 The MICs of AMB were more heterogenous (range 0.75 to >32 lg ml )1 ), as previously reported.
5
COL exerted antifungal activity against G. argillacea with only indifferent effects when it was combined with VRC or AMB. However, COL plus CAS exhibited nearly 90% antagonistic effects. These in vitro findings may indicate that concomitant administration of COL and CAS is less effective in treating G. argillacea infections. Most studies analysing antifungal susceptibility of these fungal species have used broth dilution method (BDM), as recommended by CLSI. However, our MIC strip test results for MIC determination of Scedosporium ⁄ Pseudallescheria spp. are mostly in agreement with the results of a recent study that used BDM. 20 A previous study used Etest to test E. dermatitidis and found that isolates were susceptible to CAS. 32 Other studies using BDM found results similar to ours. 33, 34 In agreement with Pfaller et al. [24] , we observed that in case of discrepancies, the MIC values for VRC tend to be lower with a strip test than with BDM. In our study, we used MIC test strips to determine the activity of combinations of agents against filamentous fungi. A previous study demonstrated that Etest could be used successfully to test antifungal interactions for Candida spp. 25 However, one limitation of our study is that we did not compare the results of MIC strip interaction testing with the results achieved by BDM.
To the best of our knowledge, no previous studies have tested the activity of COL as single agent or in combination with other antifungal agents against fungi of the genera Scedosporium ⁄ Pseudallescheria, Exophiala and Geosmithia. COL is the first agent to demonstrate activity against multidrug-resistant S. prolificans. Interaction testing with three antifungal agents demonstrated that VRC appears to be the best combination partner for COL, because almost no antagonism was observed for most species.
In conclusion, we have provided new insights into the antifungal in vitro activity of COL. Although the mode of action and cellular target of COL in fungi remains unclear, this substance shows antifungal activity against different filamentous ascomycetes. As our evidence is based on in vitro data only, our future perspective is to verify the results by in vivo animal models. Furthermore, clinical trials are needed to study the antifungal activity of COL in humans.
